Aims: Randomized controlled trials have reported an association between pioglitazone and reduced incidence of stroke in type 2 diabetic (T2DM) and insulin-resistant populations. We investigated this association within a real-world database. Two non-exposed control cohorts were matched according to age, gender, HbA1c, diabetes duration, stroke history, co-morbidities and prior T2DM regimen. Control cohort-1 comprised patients initiating a new T2DM therapy as their respective case initiated pioglitazone. Control cohort-2 maintained the same T2DM regimen as their respective case prior to the case initiating pioglitazone. Primary outcome was incident stroke; other outcomes included mortality, length of hospital stay and stroke recurrence.
properties that may improve other risk factors associated with cerebrovascular disease, such as dyslipidaemia, 8 blood pressure 9 and inflammation. The drug may also have direct anti-atherosclerotic effects via PPAR-γ, the nuclear transcription factor activated by this class of drugs. In the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study, pioglitazone therapy was associated with a markedly reduced incidence of stroke in patients with type 2 diabetes and a prior history of stroke. 10, 11 Recent data concerning insulin-resistant, but non-diabetic, patients with a prior history of stroke or transient ischemic attack (TIA) from the Insulin Resistance
Intervention after Stroke (IRIS) trial [12] [13] [14] also indicated a benefit in reducing recurrent stroke and myocardial infarction.
While prospective randomized trials may be considered a gold standard that allows for the equalisation of differences between groups, the inclusion/exclusion criteria applied can reduce the study population to a non-representative sub-set of those who will receive therapy in real-life clinical practice. The aim of this study, therefore, was to determine whether the reduced incidence of stroke associated with pioglitazone is observed within a retrospective, UK database derived from day-to-day primary care practice.
| METHODS

| Data source
The study was conducted using data from the Clinical Practice
Research Datalink (CPRD). 15 The core dataset within CPRD is CPRD GOLD which comprises anonymized, longitudinal data from approximately 700 primary care practices within the UK. Available data include patient demographics, diagnoses, prescription history for prescriptions emanating in primary care, and laboratory test results. For a sub-cohort of those primary care practices based in England, linkage to other data sources has been undertaken. The linked data sources used within this study were the Health Episodes Statistics (HES), 16 providing details of inpatient hospital contacts, and the Office of National Statistics (ONS) 17 mortality dataset.
| Patient selection
Patients eligible for linkage to HES and ONS, who were of acceptable research quality as defined by CPRD, were selected for this study.
Patients with type 2 diabetes were identified by previously used algorithms 18 that select patients based on diagnostic codes and treatment history. A wash-in period of at least 90 days from the latest patient registration date and the practice's up-to-standard date of the patient's first recorded diagnosis of diabetes was required to allow selection from an approximate type 2 diabetes incident population.
From this pool of patients, those who initiated pioglitazone between January 1, 2000 and December 31, 2012 were selected.
Patients with a prior history of heart failure were excluded as the drug is contraindicated for this population. The date of first prescription for pioglitazone was defined as the case index date. Duration of treatment was defined as the period from index date to date of the last prescription in the regimen, that is, prior to change of any regimen component, augmented by the estimated duration of that prescription. If the duration could not be calculated, a default value of 28 days was used.
Pioglitazone-exposed patients were matched to two control cohorts at a ratio of 1:1. The pool of control patients comprised those with an incident diagnosis of type 2 diabetes, no history of heart failure, and no history of receiving a TZD at any point in their patient record.
The first control cohort was comprised of individuals who were undergoing the same previous glucose-lowering regimen as their respective case and who changed to a different (ie, non-TZD) glucoselowering therapy within 180 days of the case index date. The index date for controls was defined as the date of medication change. The second control cohort included those who remained on the same glucose-lowering regimen as their respective case prior to the case initiating pioglitazone. The index date for these controls was defined as the date of the control's initiation with that therapy, plus the duration of the regimen of their respective case prior to the addition of pioglitazone.
For both control cohorts, the following matching criteria were used: age (AE3 years), gender, HbA1c (AE1%), duration of diagnosed diabetes (AE1 year), history of stroke prior to index date, Charlson comorbidity index matching on scores of 1, 2 or 3+, and same glucoselowering drug class combination immediately prior to index date.
| Outcomes
The primary outcome was time to first stroke post index date. Incident stroke events were defined by Read code within the CPRD GOLD database or ICD-10 code in either the HES or ONS datasets. Secondary outcomes were proportion of first stroke events that resulted in death within 28 days (fatal stroke), inpatient length of stay following hospital admission for stroke, recurrence of stroke.
| Statistical analysis
Baseline characteristics were compared using the chi-squared test for categorical variables and the t-test for continuous variables. All analyses were performed twice, first with follow-up restricted to the ontreatment period, that is, the time the patient remained on the index regimen, defined as the date of last prescription plus 90 days, and second with follow-up for the entire period within the database.
For the primary outcome, time to first stroke was evaluated using Patients are able to decline inclusion in the CPRD; thus, their data is not extracted from their particular primary care practice.
3 | RESULTS
| Identified patients and baseline characteristics
A total of 7577 patients who initiated with pioglitazone met the initial study inclusion criteria. Of these pioglitazone patients, 4234 (55.9%)
could be matched at a ratio of 1:1 to the first control cohort and 3604
(47.6%) could be matched to the second. Baseline characteristics for each matched cohort are shown in Tables 1 and 2 and for controls was metformin and sulfonylurea (33.5%) (Tables S1
and S2).
| Primary outcome
In comparison with control cohort-1, the rate of stroke events while a n (%).
b Mean (standard deviation).
analysis that followed patients for the entire follow-up period, the respective rates were 7.2 vs 8.5 events per kpy of exposure, with a crude relative rate of 0.844 (0.672-1.060) ( Table 3 ). The HR was 0.773 (0.611-0.978) (Figure 1 ). Table S3 presents hazard ratios for patients with and without prior history of stroke.
| Secondary outcomes 3.3.1 | Stroke recurrence and mortality
There was no difference between cases and controls in the 30-day mortality rate following the index stroke event. For events observed during the on-treatment period, the proportion of deaths was 12.0% vs 12.7% (P = .444) for control cohort-1 and 8.8% vs 10.1% (P = .358) for control cohort-2. Following patients until the end of the observed period, the respective figures were 10.3% vs 12.3% (P = .121) and 11.1% vs 11.8% (P = .832) ( Table 4 ).
There was also no significant difference in the rate of recurrent strokes in each control cohort over either follow-up period. (Table S4 ).
| Hospital outcomes
For those incident stroke events that resulted in hospital admission, there was no significant difference in overall length of stay for control cohort 1 during either the on-treatment follow-up period (4.0 days vs 5.0; P = .419) or the entire follow-up period (7.0 vs 6.0; P = .417).
There was also no significant difference when considering those admissions that resulted in discharge to the patient's usual place of residence: 3.0 days vs 3.0 (P = .645) and 6.0 vs 3.0 (P = .196), respectively (Table 5) .
For cohort 2, however, there was a significant difference in length of stay for admission due to incident stroke during the on-treatment period (3.0 days vs 8.0; P = .002) but no significant difference over the entire follow-up period (6.0 days vs 7.0; P = .941). For those admissions resulting in discharge to the patient's usual place of residence, there was a significant difference for those events occurring during the therapy period (3.0 vs 7.0; P = .008). However, for the entire follow-up period, there was no significant difference (5.0 vs 6.0; P = .485) ( Table 5 ).
| DISCUSSION
In this study, we have shown a significantly reduced risk of incident stroke in patients treated with pioglitazone compared with matched controls using other glucose-lowering agents for T2DM. This was observed in both control sets and during both follow-up periods.
Interestingly, hazard ratios were lower during the on-treatment period compared with the entire follow-up period in both control sets. If the association we find is related causally to pioglitazone treatment, this observation suggests an attenuation of treatment effect over time, as suggested in long-term follow-up of the original PROactive cohort.
14 There was no difference in secondary outcomes concerning proportion of incident strokes that resulted in death or time to recurrent stroke between cases and controls in either control cohort or over either follow-up period. In each, however, the odds ratio was below unity, with wide confidence limits, likely because of small numbers.
For strokes resulting in hospitalization of patients in control set 1, there was no significant difference in overall length of stay or in discharge to the patient's usual place of residence for either the ontreatment period or the entire follow-up period. For patients in control set 2, the length of stay was significantly lower overall for patients Perhaps not surprisingly, as both were numerically dominated by that trial, 2 meta-analyses have reported a similar reduced relative risk of stroke in patients treated with pioglitazone in the PROactive study.
Lincoff and colleagues reported a relative risk of 0.80 (0.62-1.04) 19 in patients with type 2 diabetes, whereas Liao and colleagues reported 0.78 (0.60-1.02) 20 in studies that also included data from IRIS.
The precise mechanism that could explain these results is not clear. It is known that, in addition to its impact on insulin sensitivity, pioglitazone affects other risk factors for cerebrovascular disease. In the IRIS trial, for example, the profile of a range of risk factors including blood glucose, blood pressure, certain lipids and the inflammatory marker, C-reactive protein, were improved 12 . Similar observations have also been reported in other investigations. 9, 21, 22 There may also be direct salutary effects via activation of PPAR-γ on the vascular endothelium, thrombotic factors, as well as on cellular elements involved in the development of atheroma. 23 To provide comparable controls, we matched patients directly on a broad range of demographic, treatment and clinical characteristics.
As a result, we were able to match approximately 50% (4234; 55.9%
to the first control cohort and 3604; 47.6% to the second control cohort) of our original pioglitazone pool. This reduced the power of the study, especially for those outcomes related to occurrence of strokes, such as mortality and length of stay, and also risk of recurrent stroke. Similar studies using routine data from different cohorts would be of interest to confirm the magnitude of our findings.
We used 2 cohorts of control for this study. The purpose of this was to partly address the issues of confounding by indication that are inherent in pharmaco-epidemiolgical studies.
Control cohort-1 involved patients whose regimen had been changed at the same time as that of their control and thus, to some extent, were at a similar stage in the treatment pathway. However, it should be noted that, for reasons of physician preference, contraindication or other factors, pioglitazone was not prescribed, and thus, confounding by indication may remain. For example, given the drug's salt-retaining properties and the contraindication in cases of heart failure, patients with suspected left ventricular dysfunction, without diagnosed heart failure, which was an exclusion, who may have been at inherently higher risk of stroke, may have received prescriptions for other agents. to have an impact on diabetes progression and outcome, is not systematically recorded within the CPRD dataset, and thus was excluded as a potential confounding variable. However, we do not believe that there would be significant differences among ethnic groups in prescription rates for pioglitazone. Furthermore, exposure to the regimens can be understood only as intention-to-treat on the part of the prescriber. From the data source, it is not possible to determine whether the patient collected the prescribed drug or whether the patient undertook treatment at the prescribed dosage. Because of the different side-effects of different therapies, it is possible that adherence rates between treatment groups may have differed. Unlike a trial situation, real-world observational studies may not contain key information recorded at baseline or at subsequent follow-up periods; missing data are thus inevitable. It is unlikely that data would be missing randomly but, more likely, will reflect the number of healthcare contacts an individual has had, and therefore can be considered a proxy for morbidity. Within this study we categorized key variables, with "missing" included as a category in order to maximize patient numbers, but we may have lost some of the granularity of this data. It is therefore important to consider this in the interpretation of results.
The quality of coding of outcomes in routine data has been questioned but, within the CPRD and HES, the quality of data is considered reasonably robust. [24] [25] [26] While some events may be misdiagnosed, incorrectly transcribed or omitted, we do not consider it likely that there would be a differential bias in error rates between the cohorts and, thus, while the absolute number of events may be questioned, the relative difference between treatment arms should persist.
In conclusion, this study revealed a significant reduction in incident stroke for patients treated with pioglitazone compared with other glucose-lowering strategies; the patients were matched to controls in two analysis cohorts and were tracked over two follow-up periods. There was no clear effect, however, on stroke mortality, recurrent stroke or hospital length of stay. These data support the findings of the PROactive study in patients with type 2 diabetes and established macrovascular disease and also from the IRIS study in patients with insulin resistance but without diabetes. Further study of the beneficial effects of this insulin-sensitizing drug in patients with, or at risk of, cerebrovascular disease is warranted. As a result of the consistency of the findings across randomized trials and observational data sets, guideline committees should now consider a recommendation to use pioglitazone, barring contraindications, in prevention of secondary stroke, at least in patients with type 2 diabetes.
